Overview of lenvatinib as a targeted therapy 
for advanced hepatocellular carcinoma

Obaid Rehman; Urooj Jaferi; Inderbir Padda; Nimrat Khehra; Harshan Atwal; Dina Mossabeh; Ranvir Bhangu

doi:10.5114/ceh.2021.109312

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2021
vol. 7

Send email

Copy url:

abstract:

Review article

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma

Obaid Rehman

¹

,

Urooj Jaferi

¹

,

Inderbir Padda

²

,

Nimrat Khehra

³

,

Harshan Atwal

³

,

Dina Mossabeh

⁴

,

Ranvir Bhangu

⁵

Hamilton Medical Center, USA
University of Washington, USA
Saint James School of Medicine, Anguilla
Windsor University School of Medicine, Saint Kitts and Nevis
Caribbean Medical University, Anguilla

Clin Exp HEPATOL 2021; 7, 3: 249-257

DOI: https://doi.org/10.5114/ceh.2021.109312

Online publish date: 2021/10/11

View full text Get citation

PlumX metrics:

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Patients commonly present with advanced/unresectable HCC where several treatment options are not effective. In this review, the authors discuss the indications and usage of lenvatinib, a multikinase inhibitor, as first-line therapy for advanced/unresectable HCC, its mode of action, efficacy, drug reactions, response to treatment and adverse effects. Since its approval in 2007, sorafenib has been used as first-line therapy for unresectable HCC. In 2018, a phase III multinational REFLECT trial on subjects with unresectable HCC (Child-Pugh class A) demonstrated that lenvatinib was non-inferior compared to sorafenib for overall survival, with a controllable toxicity profile, leading to its approval. In addition, our review discusses studies that compare the safety and efficacy profile of lenvatinib especially in patients who have a decline in their liver function to Child-Pugh class B. A current real world analysis of lenvatinib approval for unresectable HCC worldwide is reported.

keywords:

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma

Obaid Rehman 1 , Urooj Jaferi 1 , Inderbir Padda 2 , Nimrat Khehra 3 , Harshan Atwal 3 , Dina Mossabeh 4 , Ranvir Bhangu 5

lenvatinib, hepatocellular carcinoma, tyrosine kinase inhibitor, hepatocellular carcinoma target therapy, lenvatinib real-world analysis

Obaid Rehman

¹

,

Urooj Jaferi

¹

,

Inderbir Padda

²

,

Nimrat Khehra

³

,

Harshan Atwal

³

,

Dina Mossabeh

⁴

,

Ranvir Bhangu

⁵